1. Kennedy SH, Lam RW, McIntyre RS et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the man- agement of adults with major depressive disorder: Section 3. Pharmaco- logical treatments. Can. J. Psychiatry 2016; 61: 540–560.
2. Rush JA, Trivedi MH, Wisniewski SR et al. STAR-D (2006; AjPsych) tiered approach for depression. Am. J. Psychiatry 2006; 163: 1905–1917.
3. Breitenstein B, Scheuer S, Holsboer F. Are there meaningful biomarkers of treatment response for depression? Drug Discov. Today 2014; 19: 539–561.
4. Fernie AR, Trethewey RN, Krotzky AJ et al. Metabolite profiling: From diagnostics to systems biology. Nat. Rev. Mol. Cell Biol. 2004; 5: 763–769.
5. Kaddurah-Daouk R, Krishnan KRR. Metabolomics: A global biochemi- cal approach to the study of central nervous system diseases. Neuropsychopharmacology 2009; 34: 173–186.
6. Kaddurah-Daouk R, Boyle SH, Matson W et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpa- tients: A proof of concept. Transl. Psychiatry 2011; 1: 1–7.
7. Zhu H, Bogdanov MB, Boyle SH et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possi- ble role for Methoxyindole pathway. PLoS One 2013; 8: 1–12.
8. Ji Y, Hebbring S, Zhu H et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 2011; 89: 97–104.
9. Sun Y, Drevets W, Turecki G et al. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine. Brain Behav. Immun. 2020; 87: 404–412.
10. Erabi H, Okada G, Shibasaki C et al. Kynurenic acid is a potential over- lapped biomarker between diagnosis and treatment response for depres- sion from metabolome analysis. Sci. Rep. 2020; 10: 1–8.
11. Ogyu K, Kubo K, Noda Y et al. Kynurenine pathway in depression: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2018; 90: 16–25.
12. Arnone D, Saraykar S, Salem H et al. Role of kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies. Neurosci. Biobehav. Rev. 2018; 92: 477–485.
13. Marx W, McGuinness AJ, Rocks T et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: A meta- analysis of 101 studies. Mol. Psychiatry 2021; 26: 4158–4178.
14. Miller JM, Schneck N, Siegle GJ et al. FMRI response to negative words and SSRI treatment outcome in major depressive disorder: A preliminary study. Psychiatry Res - Neuroimaging 2013; 214: 296–305.
15. Ruhé HG, Booij J, Veltman DJ et al. Successful pharmacologic treat- ment of major depressive disorder attenuates amygdala activation to neg- ative facial expressions: A functional magnetic resonance imaging study.J. Clin. Psychiatry 2012; 73: 451–459.
16. Alexopoulos GS, Hoptman MJ, Kanellopoulos D et al. Functional con- nectivity in the cognitive control network and the default mode network in late-life depression. J. Affect. Disord. 2012; 139: 56–65.
17. Yuan H, Zhu X, Tang W et al. Connectivity between the anterior insula and dorsolateral prefrontal cortex links early symptom improvement to treatment response. J. Affect. Disord. 2020; 260: 490–497.
18. Yamamura T, Okamoto Y, Okada G et al. Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: A resting-state fMRI study using fractional amplitude of low-frequency fluctuations. Transl. Psychiatry 2016; 6: e754–e754.
19. Gong J, Wang J, Qiu S et al. Common and distinct patterns of intrinsic brain activity alterations in major depression and bipolar disorder: Voxel-based meta-analysis. Transl. Psychiatry. 2020; 10: 353. https://doi. org/10.1038/s41398-020-01036-5.
20. Argyelan M, Lencz T, Kaliora S et al. Subgenual cingulate cortical activ- ity predicts the efficacy of electroconvulsive therapy. Transl. Psychiatry 2016; 6: 4–9.
21. Egorova N, Veldsman M, Cumming T et al. Fractional amplitude of low- frequency fluctuations (fALFF) in post-stroke depression. NeuroImage Clin 2017; 16: 116–124.
22. Liu CH, Ma X, Song LP et al. Abnormal spontaneous neural activity in the anterior insular and anterior cingulate cortices in anxious depression. Behav. Brain Res. 2015; 281: 339–347.
23. Guo W, Liu F, Zhang J et al. Dissociation of regional activity in the default mode network in first-episode, drug-naive major depressive disor- der at rest. J. Affect. Disord. 2013; 151: 1097–1101.
24. Al-Zubaidi A, Heldmann M, Mertins A et al. Influences of hunger, sati- ety and Oral glucose on functional brain connectivity: A multimethod resting-state fMRI study. Neuroscience 2018; 382: 80–92.
25. Al-Zubaidi A, Mertins A, Heldmann M et al. Machine learning based classification of resting-state fMRI features exemplified by metabolic state (hunger/satiety). Front. Hum. Neurosci. 2019; 13. Epub ahead of print. https://doi.org/10.3389/fnhum.2019.00164.
26. Hamilton M. Development of a rating scale for primary depressive ill- ness. Br. J. Soc. Clin. Psychol. 1967; 6: 278–296.
27. Otsubo T, Tanaka K, Koda R et al. Reliability and validity of Japanese version of the Mini-international neuropsychiatric interview. Psychiatry Clin. Neurosci. 2005; 59: 517–526.
28. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
lin. Psychiatry 1998; 59: 22–33.
29. Oldfield RC. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia 1971; 9: 97–113.
30. Matsuoka K, Uno M, Kasai K et al. Estimation of premorbid IQ in indi- viduals with Alzheimer’s disease using Japanese ideographic script (kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin. Neurosci. 2006; 60: 332–339.
31. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: A functional connectivity toolbox for correlated and Anticorrelated brain networks. Brain Connect. 2012; 2: 125–141.
32. Zou QH, Zhu CZ, Yang Y et al. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: Fractional ALFF. J. Neurosci. Methods 2008; 172: 137–141.
33. Küblböck M, Woletz M, Höflich A et al. Stability of low-frequency fluc- tuation amplitudes in prolonged resting-state fMRI. Neuroimage 2014; 103: 249–257.
34. Zuo XN, Xing XX. Test-retest reliabilities of resting-state FMRI mea- surements in human brain functional connectomics: A systems neurosci- ence perspective. Neurosci. Biobehav. Rev. 2014; 45: 100–118.
35. Zuo XN, Di Martino A, Kelly C et al. The oscillating brain: Complex and reliable. Neuroimage 2010; 49: 1432–1445.
36. Friedman L, Stern H, Brown GG et al. Test-retest and between-site reli- ability in a multicenter fMRI study. Hum. Brain Mapp. 2008; 29: 958–972.
37. Feis RA, Smith SM, Filippini N et al. ICA-based artifact removal dimin- ishes scan site differences in multi-center resting-state fMRI. Front Neu- rosci 2015; 9. Epub ahead of print. https://doi.org/10.3389/fnins.2015. 00395.
38. Rath J, Wurnig M, Fischmeister F et al. Between- and within-site vari- ability of fMRI localizations. Hum. Brain Mapp. 2016; 37: 2151–2160.
39. Dansereau C, Benhajali Y, Risterucci C et al. Statistical power and pre- diction accuracy in multisite resting-state fMRI connectivity. Neuroimage 2017; 149: 220–232.
40. Fortin JP, Parker D, Tunç B et al. Harmonization of multi-site diffusion tensor imaging data. Neuroimage 2017; 161: 149–170.
41. Fortin J-P, Cullen N, Sheline YI et al. Harmonization of cortical thick- ness measurements across scanners and sites. Neuroimage 2018; 167: 104–120.
42. Yu L, Long Q, Tang Y et al. Improving Emotion Regulation through Real-Time Neurofeedback Training on the Right Dorsolateral Prefrontal Cortex: Evidence from Behavioral and Brain Network Analyses. Front. Hum. Neurosci. 2021; 15: 1–11.
43. Ochsner K, Gross J. The cognitive control of emotion. Trends Cogn. Sci.2005; 9: 242–249.
44. Ochsner KN, Silvers JA, Buhle JT. Functional imaging studies of emo- tion regulation: A synthetic review and evolving model of the cognitive control of emotion. Ann. N. Y. Acad. Sci. 2012; 1251: E1–E24.
45. Buhle JT, Silvers JA, Wage TD et al. Cognitive reappraisal of emotion: A meta-analysis of human neuroimaging studies. Cereb. Cortex 2014; 24: 2981–2990.
46. Kohn N, Eickhoff SB, Scheller M et al. Neural network of cognitive emotion regulation - an ALE meta-analysis and MACM analysis. Neuroimage 2014; 87: 345–355.
47. MacDonald AW. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science (80- ) 2000; 288: 1835–1838.
48. Vanderhasselt MA, De Raedt R, Leyman L et al. Acute effects of repeti- tive transcranial magnetic stimulation on attentional control are related to antidepressant outcomes. J. Psychiatry Neurosci. 2009; 34: 119–126.
49. Menon V. Large-scale brain networks and psychopathology: A unifying triple network model. Trends Cogn. Sci. 2011; 15: 483–506.
50. Wang Y, Yang S, Sun W et al. Altered functional interaction hub between affective network and cognitive control network in patients with major depressive disorder. Behav. Brain Res. 2016; 298: 301–309.
51. Rayner G, Jackson G, Wilson S. Cognition-related brain networks under- pin the symptoms of unipolar depression: Evidence from a systematic review. Neurosci. Biobehav. Rev. 2016; 61: 53–65.
52. Koenigs M, Grafman J. The functional neuroanatomy of depression: Dis- tinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res. 2009; 201: 239–243.
53. Okada G, Okamoto Y, Morinobu S et al. Attenuated left prefrontal acti- vation during a verbal fluency task in patients with depression. Neuro- psychobiology 2003; 47: 21–26.
54. Okada G, Okamoto Y, Yamashita H et al. Attenuated prefrontal activa- tion during a verbal fluency task in remitted major depression. Psychiatry Clin. Neurosci. 2009; 63: 423–425.
55. Takamura M, Okamoto Y, Okada G et al. Disrupted brain activation and deactivation pattern during semantic verbal fluency task in patients with major depression. Neuropsychobiology 2017; 74: 69–77.
56. AL B, Saxena S, MA M et al. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol. Psychia- try 2001; 50: 171–178.
57. Fitzgerald PB, Laird AR, Maller J et al. A meta-analytic study of changes in brain activation in depression. Hum. Brain Mapp. 2008; 29: 683–695.
58. Shajahan PM, Glabus MF, Steele J et al. Left dorso-lateral repetitive transcranial magnetic stimulation affects cortical excitability and func- tional connectivity, but does not impair cognition in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2002; 26: 945–954.
59. Walsh ND, Williams SCR, Brammer MJ et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depres- sion after antidepressant therapy. Biol. Psychiatry 2007; 62: 1236–1243.
60. Fales CL, Barch DM, Rundle MM et al. Antidepressant treatment nor- malizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. J. Affect. Disord. 2009; 112: 206–211.
61. Mayberg HS, Brannan SK, Tekell JL et al. Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol. Psychiatry 2000; 48: 830–843.
62. Kennedy SH, Evans KR, Krüger S et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry 2001; 158: 899–905.
63. Umehara H, Numata S, Watanabe S et al. Altered KYN/TRP, Gln/Glu, and met/methionine sulfoxide ratios in the blood plasma of medication- free patients with major depressive disorder. Sci. Rep. 2017; 7: 4855.
64. Haroon E, Welle JR, Woolwine BJ et al. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depres- sion. Neuropsychopharmacology 2020; 45: 998–1007.
65. Kocki T, Wnuk S, Kloc R et al. New insight into the antidepressants action: Modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. J. Neural Transm. 2012; 119: 235–243.
66. G´al EM, Sherman AD. L-kynurenine its synthesis and possible regula- tory function in brain. Neurochem. Res. 1980; 5: 223–239.
67. Fukui S, Schwarcz R, Rapoport SI et al. Blood?Brain barrier transport of kynurenines: Implications for brain synthesis and metabolism.J. Neurochem. 1991; 56: 2007–2017.
68. G´al EM, Sherman AD. Synthesis and metabolism of l-kynurenine in rat brain. J. Neurochem. 1978; 30: 607–613.
69. Kita T, Morrison PF, Heyes MP et al. Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain.J. Neurochem. 2002; 82: 258–268.
70. Vécsei L, Szal´ardy L, Fülöp F et al. Kynurenines in the CNS: Recent advances and new questions. Nat. Rev. Drug Discov. 2013; 12: 64–82.
71. Hestad KA, Engedal K, Whist JE et al. The relationships among trypto- phan, kynurenine, indoleamine 2,3-dioxygenase, depression, and neuro- psychological performance. Front. Psychol. 2017; 8: 1–8.
72. Zhou Y, Zheng W, Liu W et al. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depres- sive disorder. Psychoneuroendocrinology 2019; 101: 72–79.
73. Solvang SEH, Nordrehaug JE, Tell GS et al. The kynurenine pathway and cognitive performance in community-dwelling older adults. The Hordaland health study. Brain Behav. Immun. 2019; 75: 155–162.
74. Stone TW, Darlington LG. The kynurenine pathway as a therapeutic tar- get in cognitive and neurodegenerative disorders. Br. J. Pharmacol. 2013; 169: 1211–1227.
75. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and Per- ipherial nervous systems. Curr. Neurovasc. Res. 2005; 2: 249–260.
76. Driesen NR, McCarthy G, Bhagwagar Z et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol. Psychiatry 2013; 18: 1199–1204.
77. Guidi M, Kumar A, Foster TC. Impaired attention and synaptic senes- cence of the prefrontal cortex involves redox regulation of NMDA recep- tors. J. Neurosci. 2015; 35: 3966–3977.
78. Rodermund P, Westendorff S, Nieder A. Blockage of NMDA- and GABA(A) receptors improves working memory selectivity of primate prefrontal neurons. J. Neurosci. 2020; 40: 1527–1537.
79. Lee J, van den Buuse M, Nithianantharajah J et al. Acute NMDA recep- tor antagonism impairs working memory performance but not attention in rats—Implications for the NMDAr hypofunction theory of schizophre- nia. Behav. Neurosci. 2020; 134: 323–331.
80. Wang M, Yang Y, Wang C-J et al. NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 2013; 77: 736–749.
81. van Vugt B, van Kerkoerle T, Vartak D et al. The contribution of AMPA and NMDA receptors to persistent firing in the dorsolateral prefrontal cortex in working memory. J. Neurosci. 2020; 40: 2458–2470.
82. Zhao J. Plasma kynurenic acid/tryptophan ratio: A sensitive and reliable bio- marker for the assessment of renal function. Ren. Fail. 2013; 35: 648–653.
83. Martin KS, Azzolini M, Lira RJ. The kynurenine connection: How exer- cise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain. Am. J. Physiol. 2020; 318: C818–C830.
論文の公開元へ
